Allogene Therapeutics (ALLO) Projected to Post Quarterly Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO) is projected to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $0.0020 million for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.05. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Trading Down 4.8%

Shares of NASDAQ ALLO opened at $1.18 on Tuesday. The business has a fifty day simple moving average of $1.22 and a 200 day simple moving average of $1.25. The firm has a market capitalization of $261.82 million, a price-to-earnings ratio of -1.06 and a beta of 0.42. Allogene Therapeutics has a one year low of $0.86 and a one year high of $3.78.

Insider Transactions at Allogene Therapeutics

In other Allogene Therapeutics news, CFO Geoffrey M. Parker sold 36,744 shares of the stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $1.26, for a total value of $46,297.44. Following the transaction, the chief financial officer owned 1,276,796 shares of the company’s stock, valued at approximately $1,608,762.96. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 13.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Allogene Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co lifted its stake in Allogene Therapeutics by 142.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company’s stock valued at $35,000 after buying an additional 18,314 shares during the period. Cerity Partners LLC lifted its stake in Allogene Therapeutics by 5.2% in the second quarter. Cerity Partners LLC now owns 400,267 shares of the company’s stock valued at $452,000 after buying an additional 19,843 shares during the period. Rhumbline Advisers lifted its stake in Allogene Therapeutics by 14.0% in the second quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock valued at $237,000 after buying an additional 25,628 shares during the period. Engineers Gate Manager LP acquired a new position in Allogene Therapeutics in the second quarter valued at about $37,000. Finally, Bank of America Corp DE lifted its stake in Allogene Therapeutics by 4.1% in the second quarter. Bank of America Corp DE now owns 987,495 shares of the company’s stock valued at $1,116,000 after buying an additional 38,686 shares during the period. Institutional investors and hedge funds own 83.63% of the company’s stock.

Analysts Set New Price Targets

ALLO has been the subject of a number of recent research reports. JMP Securities restated a “market perform” rating on shares of Allogene Therapeutics in a research note on Monday, August 4th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Allogene Therapeutics in a research note on Friday, October 10th. Wall Street Zen lowered Allogene Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Allogene Therapeutics in a research note on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.44.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).